Profits in cancer research and treatment
On Barchart Portfolio Blogs I bring to your attention stocks you might want to consider for your portfolio.
YM BioSciences Inc.(YMI) is being added to the Barchart Van Meerten Speculative portfolio. The company engages in the licensing and commercialization of drug products and technologies primarily for the treatment of cancer or cancer-related conditions worldwide. Its approved product Nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor, is used for the treatment of nasopharyngeal carcinomas, head and neck cancer, refractory children glioma, adult glioma, and stage III/IV glioma. The company is also developing Nimotuzumab for various other epithelial cancers; and AeroLEF, a proprietary formulation of free and liposome-encapsulated fentanyl administered by pulmonary inhalation for the treatment of severe and moderate acute pain, including cancer pain.
Recent price appreciation of 16.24% last month plus hitting 11 new highs in the last 20 trading sessions is a reason to take notice. Barchart Trend Spotter (tm) signals a buy and the stock is trading above its 20, 50 and 100 day moving averages. The stock trades at 1.36 with a 50 day moving average of 1.28.
Wall Street brokerages have 2 buy recommendations for their clients based on a prediction of a 190.70% sales increase next year. Earnings per share are estimated to increase 13.00% this year and 25.00% next year. Pretty aggressive estimates.
The investing community has noticed this stock and the Motley Fool CAPS members think the stock will beat the market by a vote of 91 to 1.
The reasons I'm adding YM Biosciences (YMI) to the Barchart Van Meerten Speculative portfolio:
1 - 11 new highs in the last 20 sessions
2 - Barchart Trend Spotter (tm) buy signal
3 - Wall Street recommendations to buy based on increased sales and earnings
4 - Positive investor sentiment
Jim Van Meerten is an investor who writes on investing here and on Barchart Portfolio Blogs. Please leave a comment below or email JimVanMeerten@gmail.com.
Disclosure: No positions in the stock mentioned at the time of publication